Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial

Author:

Woznitza NickORCID,Ghimire Bhagabati,Devaraj Anand,Janes Sam MORCID,Piper Keith,Rowe Susan,Bhowmik AngshuORCID,Hayes Natasha,Togher Daniel,Arumalla Nikita,Skyllberg Erik,Au-Yong Iain T H,Geary Susan,George Bindu,Sheard Sarah,Ellis Stephen,Shah Zoheb,Maughn Sue,Duffy Stephen W,Baldwin DavidORCID

Abstract

The National Optimal Lung Cancer Pathway recommends rapid progression from abnormal chest X-rays (CXRs) to CT. The impact of the more rapid reporting on the whole pathway is unknown. The aim of this study was to determine the impact of immediate reporting of CXRs requested by primary care by radiographers on the time to diagnosis of lung cancer.MethodPeople referred for CXR from primary care to a single acute district general hospital in London attended sessions that were prerandomised to either immediate radiographer (IR) reporting or standard radiographer (SR) reporting within 24 hours. CXRs were subsequently reported by radiologists blind to the radiographer reports to test the reliability of the radiographer report. Radiographer and local radiologist discordant cases were reviewed by thoracic radiologists, blinded to reporter.Results8682 CXRs were performed between 21 June 2017 and 4 August 2018, 4096 (47.2%) for IR and 4586 (52.8%) for SR. Lung cancer was diagnosed in 49, with 27 (55.1%) for IR. The median time from CXR to diagnosis of lung cancer for IR was 32 days (IQR 19, 70) compared with 63 days (IQR 29, 78) for SR (p=0.03).8258 CXRs (95.1%) were reported by both radiographers and local radiologists. In the 1361 (16.5%) with discordance, the reviewing thoracic radiologists were equally likely to agree with local radiologist and radiographer reports.ConclusionsImmediate reporting of CXRs from primary care reduces time to diagnosis of lung cancer by half, likely due to rapid progress to CT. Radiographer reports are comparable to local radiologist reports for accuracy.Trial registrationInternational Standard Randomised Controlled Trial NumberISRCTN21818068. Registered on 20 June 2017.

Funder

Cancer Research UK

Publisher

BMJ

Subject

Pulmonary and Respiratory Medicine

Reference11 articles.

1. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study

2. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial

3. NHS England and NHS Improvement . Waiting times for suspected and diagnosed cancer patients, 2021. Available: https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2021/07/Cancer-Waiting-Times-Annual-Report-202021-Final.pdf [Accessed 05 Sept 2021].

4. NHS England . National optimal lung cancer pathway 2020, 2020. Available: https://www.cancerresearchuk.org/sites/default/files/national_optimal_lung_pathway_aug_2017.pdf [Accessed 18 Oct 2021].

5. NHSE . Faster diagnosis standard, 2020. Improvement. Available: https://www.england.nhs.uk/cancer/faster-diagnosis/#fds [Accessed 05 Sep 2021].

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3